The impact of hypo-attenuated leaflet thickening on haemodynamic valve deterioration following transcatheter aortic valve replacement

Hypo-attenuated leaflet thickening (HALT) may occur following transcatheter aortic valve replacement (TAVR), however, it remains unclear if HALT is a predictor of haemodynamic valve deterioration (HVD). To determine the impact of HALT on the occurrence of HVD. We prospectively evaluated 186 patients...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of cardiovascular computed tomography 2022-03, Vol.16 (2), p.168-173
Hauptverfasser: Rashid, Hashrul N., Michail, Michael, Ramnarain, Jaineel, Nasis, Arthur, Nicholls, Stephen J., Cameron, James D., Gooley, Robert P.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Hypo-attenuated leaflet thickening (HALT) may occur following transcatheter aortic valve replacement (TAVR), however, it remains unclear if HALT is a predictor of haemodynamic valve deterioration (HVD). To determine the impact of HALT on the occurrence of HVD. We prospectively evaluated 186 patients for the presence of HALT at a median of 6 weeks following TAVR (Interquartile-range [IQR] 4–12 weeks). HALT depth and area were measured. HVD encompassed any of the following: mean gradient ≥20 ​mmHg with an increase in gradient ≥10 ​mmHg from baseline, Doppler velocity index reduction ≥0.1 or new moderate-to-severe valvular regurgitation. Routine echocardiograms at discharge, one month and annually, were assessed by echo-cardiologists that were blinded to the HALT status. LT prevalence was 17.7% (33/186). HVD was present in 8.6% (16/186) at a median follow-up of 2 years (IQR 1–3); two required valve re-intervention and five required anticoagulation. HALT was the only independent predictor of HVD on multivariate analysis (OR 33.3, 95%CI 7.4–125). Patients with HALT were more likely to develop HVD, require repeat valve intervention and have higher trans-valvular gradients at up to 3-year follow-up. Patients with HALT had a median cumulative thickness of 2.9 ​mm (IQR 1.9–4.7) and area of 64.2 ​mm2 (IQR 40.9–91.6). Thresholds for HALT in predicting HVD were a cumulative depth of 2.4 ​mm (Specificity 94.1%, Sensitivity 75.0%, AUC ​= ​0.87) and cumulative area of 28 ​mm2 (Specificity 92.2%, Sensitivity 81.3%, AUC ​= ​0.86). HALT is an independent predictor of HVD, which exhibits specific depth and area thresholds to predict HVD. CT following TAVR may determine patients at risk of HVD. This figure demonstrates the continuum of leaflet thrombosis. Previous studies have shown that prostheses that develop hypo-attenuated leaflet thickening (HALT) may progress to restricted leaflet motion (RELM), which is associated with an increased thrombotic burden. Whether this progresses to bioprosthetic valve failure or valve thrombosis is unclear. In this study, HALT was shown to be an independent predictor of haemodynamic valve deterioration (HVD). Furthermore, a cumulative HALT depth of greater than 2.4 ​mm and cumulative area greater than 28 ​mm2 accurately predicted HVD. Patients with HALT that develop HVD may progress to bioprosthetic valve failure and clinical valve thrombosis if left unmonitored or untreated. HALT ​= ​hypo-attenuated leaflet thickening, HVD ​= ​haemodynamic
ISSN:1934-5925
1876-861X
DOI:10.1016/j.jcct.2021.11.013